Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection.
about
CD4 T-cell responses to herpes simplex virus type 2 major capsid protein VP5: comparison with responses to tegument and envelope glycoproteins.Episodic therapy for genital herpes in sub-saharan Africa: a pooled analysis from three randomized controlled trials.Seroprevalence and factors associated with herpes simplex virus type 2 among HIV-negative high-risk men who have sex with men from Rio de Janeiro, Brazil: a cross-sectional studyIncreasing prevalence of genital herpes in developing countries: implications for heterosexual HIV transmission and STI control programmesPublic Health Strategies to Prevent Genital Herpes: Where Do We Stand?Laboratory techniques in the diagnosis of herpes simplex infectionLimits in reliability of glycoprotein G-based type-specific serologic assays for herpes simplex virus types 1 and 2.Ability of a rapid serology test to detect seroconversion to herpes simplex virus type 2 glycoprotein G soon after infection.Six-year study of the incidence of herpes in genital and nongenital cultures in a central Kentucky medical center patient populationGenital herpes: review of the epidemic and potential use of type-specific serologyPremarket evaluation of a commercial glycoprotein G-based enzyme immunoassay for herpes simplex virus type-specific antibodies.Sorting out the new HSV type specific antibody tests.Challenges in genital herpes simplex virus management.Progress in meeting today's demands in genital herpes: an overview of current management.Patient and physician partnerships in managing genital herpes.Quantitative and qualitative correlates of cervicovaginal herpes simplex virus type 2 shedding among HIV-infected women in the Women's Interagency HIV Study.Clinician and patient recognition of anogenital herpes disease in HIV positive men who have sex with men.Genital herpes serotesting: a study of the epidemiology and patients' knowledge and attitude among STD clinic attenders in Coventry, UKEstimating the costs and benefits of screening monogamous, heterosexual couples for unrecognised infection with herpes simplex virus type 2.The acceptability of the introduction of a type specific herpes antibody screening test into a genitourinary medicine clinic in the United KingdomIs HSV serology useful for the management of first episode genital herpes?British Co-operative Clinical Group national survey on diagnostic issues surrounding genital herpes. MSSVD Special Interest Group on Genital Herpes and the British Co-operative Clinical GroupEfficacy results of a trial of a herpes simplex vaccine.Recent developments in genital herpes.Diagnostics for herpes simplex virus: is PCR the new gold standard?Population-level effect of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa.Detection of immunoglobulin M antibodies to glycoprotein G-2 by western blot (immunoblot) for diagnosis of initial herpes simplex virus type 2 genital infections.Suppressive valacyclovir therapy to reduce genital herpes transmission: good public health policy?Detection of asymptomatic initial herpes simplex virus (HSV) infections in animals immunized with subunit HSV glycoprotein vaccines.Seroreactive recombinant herpes simplex virus type 2-specific glycoprotein GOnce daily valacyclovir for reducing viral shedding in subjects newly diagnosed with genital herpes.Management of genital herpes simplex infection.Light microscopy, culture, molecular, and serologic methods for detection of herpes simplex virus.Prevention, recognition and management of neonatal HSV infections.2017 European guidelines for the management of genital herpes.Genital herpes: natural history and treatment of acute episodes.Herpes simplex virus infections during the decade since the licensure of acyclovir.Evaluation of an Automated Chemiluminescent Immunoassay in Typing Detection of IgG Antibodies Against Herpes Simplex Virus.2014 UK national guideline for the management of anogenital herpes.The effect of valacyclovir on HIV and HSV-2 in HIV-infected persons on antiretroviral therapy with previously unrecognised HSV-2.
P2860
Q30957753-7AE93FEE-B1A5-44B5-A126-0CB7B089414FQ31028568-79186914-16DA-47A0-8041-29149E0AB6BCQ33425027-C7BD5EB7-16AD-43CC-A6F1-E0F4A95C1149Q33885705-B8DDC865-27F0-45A1-8762-A45153935C1FQ33926487-5AFD7246-3826-431A-BD8A-80244982E348Q33934358-A875B054-46AD-4FF4-A142-DA60B1F95B95Q33958692-112E2B70-07A4-4781-A42E-8125703CA7B7Q33960473-163F623A-53F8-4C9A-9A39-5A11361C7020Q33973461-05259D31-7009-4027-BE85-30F8F490F9A6Q33975387-25AB74A3-10B9-42F5-A030-D02C645618A3Q34073676-D29FC9E0-CB14-4064-8014-3D6FDC8EEC8DQ34313806-837731B4-6C19-4F5E-915B-6AB702498558Q34918258-D065784B-907D-4CE8-8B2A-030A400C61F2Q34918299-D2F04B07-E2CF-4417-9829-1FDAF760B1C4Q34918316-EF3C663E-65CE-4DB6-BFB3-05707D5DFC2BQ35070290-392D15F9-6E71-4771-9426-4A699FFC8A6FQ35167548-A41EAC4C-2A4A-4F8A-A1E2-2F434E90F9FDQ35530334-434AC778-0035-4244-A78E-24F61432C688Q35530369-F0AECC7C-4BFD-4575-9B39-7A310077E09DQ35530421-E8C16A0C-9F3B-4582-910B-B43E638B4893Q35530758-37820B89-49A3-4EAA-AE2D-337C80551C24Q35562708-7966B1DF-6021-45FA-8887-45F5D2C64AB3Q35780697-29F94F29-EF6F-4AE5-A749-4E353B80BDF2Q35893279-2C3A2AC4-8A4F-44C5-B6D9-B1DB36D8F320Q36463219-00CF9DAA-1089-4E8C-ADFC-CAAB083F8CB7Q37014624-6F7C1153-23C4-48F2-8D61-CC85DA4BE006Q37146168-CE1B5B97-0ED3-4936-9213-8C80E1A27EAAQ37206230-989FCB0C-025A-4E26-87B7-2686670C29E1Q37224689-A9F9CE3D-2038-440E-A44D-2A98D89281AFQ37233274-FAD0EB94-BB16-4C29-911B-5E128E007970Q37299714-1F07B173-D413-4042-871D-885FA9A1C585Q37545127-221FB66A-BE4B-4EC9-A9DA-C972B6D021BBQ37546617-459C378D-1B40-446E-BCA1-1556CE867AD2Q38021849-C239FB0B-B034-4AA2-9A39-2FB19A4AF567Q40072392-8D2B9FC7-40E0-4FB1-8DBB-975ED2DF0E25Q40782518-3073BA0B-D57D-431C-8DD7-EDF5A7347B9AQ40782534-F1567148-B999-4291-BB0F-19A1147B9726Q40871917-303BA5FD-9AC2-48FD-9FA1-917348831CB3Q41345018-399FDB3A-282A-471C-910C-9513F26BFDCAQ42198575-629B870E-6C84-476F-9DFE-2B3A37A9DA9B
P2860
Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Development of clinically reco ...... implex virus type 2 infection.
@en
Development of clinically reco ...... implex virus type 2 infection.
@nl
type
label
Development of clinically reco ...... implex virus type 2 infection.
@en
Development of clinically reco ...... implex virus type 2 infection.
@nl
prefLabel
Development of clinically reco ...... implex virus type 2 infection.
@en
Development of clinically reco ...... implex virus type 2 infection.
@nl
P2093
P1476
Development of clinically reco ...... implex virus type 2 infection.
@en
P2093
P304
P356
10.7326/0003-4819-110-11-882
P407
P577
1989-06-01T00:00:00Z